Genentech Patient Foundation

The Genentech Patient Foundation operates as a fundamentally different charitable entity from traditional philanthropic foundations. Rather than making competitive discretionary grants to nonprofit organizations, it distributes free Genentech-branded prescription medications directly to financially eligible patients across the United States. Established in August 2003 as a company-sponsored operating foundation (IRS foundation code 03) and funded entirely by parent company Roche/Genentech, the Foundation received $3.71 billion in contributions in FY 2024 — all of which flowed directly to patient assistance with virtually zero administrative overhead.

This means "applying" to the Genentech Patient Foundation is not a competitive grant process. There are no letters of inquiry, no proposal narratives, no letters of support, and no peer review panels. Applications follow a standardized binary eligibility model: patients either qualify based on income and insurance status or they do not. The Foundation's role is to ensure that no Genentech medication goes unaccessed because of financial barriers.

The Foundation favors patients in three situations: (1) uninsured patients with household income below $150,000/year, (2) insured patients who cannot afford their out-of-pocket costs and meet income requirements, and (3) individuals in other qualifying financial circumstances evaluated case by case. There is no preference by disease category or geography — every medicine on the participating roster is covered, spanning oncology, immunology, ophthalmology, and neurology.

The "relationship progression" for this Foundation inverts the traditional funder model. Patients and their physicians submit two forms — a Patient Consent Form and a Prescriber Foundation Form — and receive a decision within 5 business days. Once approved, patients receive free medications on an ongoing basis without annual re-enrollment, as long as they remain financially eligible.

First-time applicants should know that the Foundation encourages exploring other financial assistance options (commercial co-pay cards, Medicaid, insurance appeals) first — not as a gatekeeping mechanism, but as practical guidance. Healthcare providers serve as the primary institutional channel: oncology practices, specialty clinics, and academic medical centers submit the majority of applications on their patients' behalf through the My Patient Solutions portal. For patients navigating the system independently, Foundation Specialists at (888) 941-3331 provide personalized guidance at no cost.

The Genentech Patient Foundation is one of the largest pharmaceutical patient assistance programs in the United States by dollar volume, and its financial trajectory reflects the rapid expansion of Genentech's biologic medicine portfolio over the past decade.

Historical giving trajectory: - FY 2013: $714M total giving, $691M grants paid, $57M assets - FY 2015: $520M total giving, $503M grants paid, $46M assets - FY 2018: $1.75B total giving, $1.71B grants paid, $141M assets - FY 2019: $2.51B total giving, $2.47B grants paid, $256M assets - FY 2020: $2.99B total giving, $2.94B grants paid, $372M assets - FY 2021: $3.32B total giving, $3.26B grants paid, $337M assets - FY 2022: $3.34B total giving, $3.28B grants paid, $367M assets - FY 2023: $3.70B total giving, $3.63B grants paid, $338M assets - FY 2024: $3.71B revenue, ~$3.58B disbursements (estimated), $424M assets

The sharpest growth occurred between FY 2018 and FY 2020, when total giving nearly doubled from $1.75B to $2.99B — a $1.24B increase in two years — driven by the expanded oncology portfolio following Roche's full acquisition of Genentech and the launch of blockbuster medicines including Tecentriq (atezolizumab) and Ocrevus (ocrelizumab).

Grant structure: Unlike traditional foundations, all IRS-reported grants flow to a single recipient category — "Eligible Patients (See Schedule #2)" — with 4 grants recorded in the most recent reporting period totaling $12.76B cumulatively across years. Individual grants represent the retail value of Genentech medicines dispensed to patients. Given that Genentech's most common Patient Foundation medicines (Herceptin, Avastin, Rituxan, Tecentriq, Ocrevus, Xolair, Lucentis) carry annual retail costs of $50,000–$200,000+ per patient, each approved enrollment represents a substantial per-patient value.

Operating efficiency: Between 97% and 99% of all annual revenue flows directly to patient assistance. Officer compensation has been $0 in every reported year. All revenue comes entirely from Genentech parent company contributions — the Foundation holds no endowment and generates no investment income, operating purely as a pass-through distribution vehicle.

Geographic scope: United States only, with all 50 states eligible. The Foundation's IRS data shows all 4 grantee records in California, reflecting the Foundation's administrative location in South San Francisco — individual patient grants are nationwide.

The Genentech Patient Foundation is classified under NTEE code P60 (Human Services — Emergency Assistance) alongside traditional philanthropic foundations, but operationally it is a pharmaceutical patient assistance program (PAP), not a competitive grantmaker. The table below compares Genentech's Patient Foundation to its closest IRS-classified peers and the most meaningful functional peer.

The Genentech Patient Foundation dwarfs all Human Services category peers in annual giving volume — $3.70B in FY 2023 versus asset bases of $209M–$375M for the traditional philanthropic peers. The Bristol-Myers Squibb Patient Assistance Foundation is the only meaningful functional comparable: both are pharmaceutical company-sponsored foundations distributing proprietary medicines to eligible patients with similar income-based eligibility thresholds and standardized application mechanics. Genentech's Foundation is nearly twice the size of BMS PAF by assets ($424M vs. $231M) and reflects the broader Genentech/Roche medicine portfolio. The remaining peers (Lamfrom, Callaway, Sea Change) operate traditional competitive grant models for nonprofits and share only the NTEE classification — not the operating model.

The Genentech Patient Foundation does not issue independent press releases about its patient assistance activities — announcements travel through Genentech's corporate communications at gene.com/media.

December 2025: Genentech announced an agreement with the U.S. government to lower Medicaid drug costs and expand direct patient access. As part of the deal, Genentech expanded its direct-to-patient program for essential medicines through TrumpRx.gov, signaling that the company is diversifying the channels through which patients access free or reduced-cost Genentech medicines beyond the traditional Patient Foundation model.

February 2026: Genentech released data on fenebrutinib as the first investigational therapy targeting Bruton's tyrosine kinase (BTK) for multiple sclerosis — a pipeline medicine that, if approved, would expand the Foundation's neurology medication roster. MS treatments like Ocrevus (ocrelizumab) are already among the highest-value Patient Foundation dispensed medicines.

November 2025: Genentech presented new data from its oncology pipeline at a major medical conference, reinforcing the breadth of existing medicines flowing through the Foundation.

Foundation administrative contacts remain unchanged: The listed contact in IRS filings is Doug McIntosh, located at 1 DNA Way MSC 24, South San Francisco, CA 94080. Foundation Specialist hotline: (888) 941-3331. No leadership transitions or program restructurings have been publicly announced for 2025–2026.

Note: The annual closure of Genentech's corporate charitable giving portal (November 27–January 2 each year) affects only the separate corporate grant programs — the Patient Foundation accepts patient applications on a continuous rolling basis with no annual interruption.

Unlike traditional foundation grant applications, the Genentech Patient Foundation process is standardized and eligibility-driven. Strategy here is not about crafting a compelling narrative — it is about submitting correctly and completely the first time.

Confirm eligibility before submitting. Use the online eligibility checker at gene.com/patients/patient-foundation/see-if-you-qualify or call (888) 941-3331 (M–F, 6 a.m.–5 p.m. PT). The income threshold for uninsured applicants is $150,000/year for households of up to 4; add $25,000 per additional household member. A 6-person household qualifies at up to $200,000/year — a figure many applicants underestimate.

Insured patients should apply too. The most common missed opportunity is assuming only uninsured patients qualify. Insured patients who cannot afford out-of-pocket costs — including high deductibles, specialty tier co-pays, or cost-sharing obligations — are eligible under a separate income-based determination. Social workers and patient navigators should screen all patients on high-cost Genentech biologics, not just the uninsured.

Submit both forms at once. The Patient Consent Form (patient) and Prescriber Foundation Form (physician) must arrive together. Incomplete submissions do not begin processing — submitting them days apart resets the timeline. Coordinate the submission between patient and provider on the same day.

Use the online portal for speed. Healthcare providers with My Patient Solutions accounts can submit digitally and track real-time status. Fax submissions to (833) 999-4363 are accepted but add variability. Text submissions to 650-877-1111 are also available. Online is fastest.

Apply immediately — no deadlines or cycles exist. The Foundation operates rolling enrollment year-round. There are no application windows, submission seasons, or funding cycles. Retroactive coverage is not available, so delays between prescription and application result in uncovered dispensing costs.

No prior authorization denials or appeals are required. Patients do not need to have insurance claims rejected before applying to the Foundation.

CellCept has a distinct process. If the prescribed medication is CellCept (mycophenolate mofetil), a separate application workflow applies — confirm details with a Foundation Specialist before submitting standard forms.

Prepare household income documentation. While the application does not require tax returns upfront, having recent income documentation ready speeds the eligibility confirmation process if the Foundation requests verification.